NEW YORK (GenomeWeb News) — Gene Logic today said it will help Solvay Pharmaceuticals identify alternative development paths for multiple undisclosed drug candidates.
 
All of these drug candidates were discontinued or de-prioritized in clinical trials for reasons other than safety.
 
Terms of the deal call for Gene Logic to pocket milestone and royalty payments similar to those paid for development-stage in-licensing deals, discounted for the fact that Solvay originally identified the compounds.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York City medical examiner is overseeing an effort to identify missing persons using DNA, according to the Associated Press.

Nobel laureate Günter Blobel has died at 81, the New York Times reports.

In PNAS this week: mouse model of genetically induced emphysema, gene expression signatures of circulating melanoma cells, and more.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.